Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4908898 | 0.98 | CYP3A4 (0.52) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL3838748 | 0.98 | CYP3A4 (0.52) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL8813083 | 0.88 | CYP3A4 (0.52) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL10975050 | 0.87 | ALDH1A1 (0.69) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL15329275 | 0.87 | CYP3A4 (0.47) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL7470284 | 0.86 | ALDH1A1 (0.67) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL8810302 | 0.85 | CYP3A4 (0.41) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL2170152 | 0.85 | EGFR (0.54) | CYP3A4ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL7471448 | 0.79 | ALDH1A1 (0.56) | CYP3A4ALDH1A1TDP1TSHRL3MBTL1 | |
| SCHEMBL8599765 | 0.78 | KMT2A (0.48) | CYP3A4ALDH1A1TDP1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290306-B | Nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2025-03-04 | — | — | CN | claimed |
| CN-118290306-A | Novel nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2024-07-05 | — | — | CN | claimed |
| CN-109574960-B | Docetaxel derivative and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-108948267-B | P (HPMA) -nitrogen mustard high molecular polymer with anti-tumor activity and preparation method and application thereof | 甘肃农业大学 | 2020-09-22 | — | — | CN | claimed |
| CN-106631857-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-propiono -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | claimed |
| CN-106631874-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-acetyl group -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | claimed |
| CN-106631857-A | Aryl nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-propionyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | claimed |
| CN-106631874-A | Arylamine nitrogen mustard derivative N,N-bis(2-chloroethyl)-N'-acetyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | claimed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| US-20090076176-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | MEDAREX, INC. (US) | 2009-03-19 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| US-20040171562-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | E. R. SQUIBB & SONS, L.L.C. | 2004-09-02 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-0891191-A1 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036616-A2 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-10-09 | — | — | WO | claimed |
| EP-0742015-A1 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1996-11-13 | — | — | EP | claimed |
| EP-0484870-A2 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1992-05-13 | — | — | EP | claimed |
| US-4017471-A | ANTITUMOR AGENT | G. D. SEARLE & CO. (EN) | 1977-04-12 | — | — | US | claimed |
| EP-4688849-A1 | BLOOD-BRAIN BARRIER CROSSING ANTIBODIES | VIB VZW (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250304677-A1 | Blood-Cerebrospinal Fluid Barrier Crossing Antibodies | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-10-02 | — | — | US | disclosed |
| US-20250297004-A1 | NECTIN-4 BINDING AGENTS | INNATE PHARMA (FR) | 2025-09-25 | — | — | US | disclosed |
| EP-4532020-A1 | NECTIN-4 BINDING AGENTS | Innate Pharma (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-118290306-B | Nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-118290306-B | Nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024208816-A1 | BLOOD-BRAIN BARRIER CROSSING ANTIBODIES | VIB VZW (BE) | 2024-10-10 | — | — | WO | disclosed |
| US-20240325557-A1 | TREATMENT OF CANCER | INNATE PHARMA (FR) | 2024-10-03 | — | — | US | disclosed |
| EP-4406585-A2 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | Factor Bioscience Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118290306-A | Novel nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2024-07-05 | — | — | CN | disclosed |
| CN-118290306-A | Novel nitrogen mustard derivative and preparation method thereof | 西南科技大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20240156987-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. | 2024-05-16 | — | — | US | disclosed |
| US-11904023-B2 | Nucleic acid products and methods of administration thereof | FACTOR BIOSCIENCE INC. (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2024008755-A1 | BLOOD-CEREBROSPINAL FLUID BARRIER CROSSING ANTIBODIES | VIB VZW (BE) | 2024-01-11 | — | — | WO | disclosed |
| US-11834513-B2 | Antibodies to MUC16 and methods of use thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023227660-A1 | NECTIN-4 BINDING AGENTS | INNATE PHARMA (FR) | 2023-11-30 | — | — | WO | disclosed |
| US-11826399-B2 | Chlorotoxin agents and uses thereof | EISAI INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-116964196-A | Recombinant oncolytic virus and medical application thereof | 深圳艾欣达伟医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4251207-A1 | TREATMENT OF CANCER | Innate Pharma (FR) | 2023-10-04 | — | — | EP | disclosed |
| CN-109574960-B | Docetaxel derivative and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20230040245-A1 | FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2023-02-09 | — | — | US | disclosed |
| US-20230015146-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. | 2023-01-19 | — | — | US | disclosed |
| US-11518996-B2 | Methods and compositions for treating cancer using peptide nucleic acid-based agents | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2022206962-A1 | RECOMBINANT ONCOLYTIC VIRUS AND MEDICAL USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2022-10-06 | — | — | WO | disclosed |
| US-11446400-B2 | Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-09-20 | — | — | US | disclosed |
| EP-2911666-B1 | MODULATORS OF RESISTANT ANDROGEN RECEPTOR | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022112356-A1 | TREATMENT OF CANCER | INNATE PHARMA (FR) | 2022-06-02 | — | — | WO | disclosed |
| EP-4003389-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | The Trustees Of Columbia University In The City Of New York (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114502202-A | Methods and compositions for treating cancer by using peptide nucleic acid-based agents | 纽约市哥伦比亚大学理事会 | 2022-05-13 | — | — | CN | disclosed |
| US-20220144898-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-05-12 | — | — | US | disclosed |
| EP-3010547-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-04-21 | — | — | EP | disclosed |
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-20200384002-A1 | Prodrugs Activated by Reduction in the Cytosol | UNIV YALE (US) | 2020-12-10 | — | — | US | disclosed |
| CN-108948267-B | P (HPMA) -nitrogen mustard high molecular polymer with anti-tumor activity and preparation method and application thereof | 甘肃农业大学 | 2020-09-22 | — | — | CN | disclosed |
| EP-2968582-B1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2020-07-01 | — | — | EP | disclosed |
| US-10675359-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2020-06-09 | — | — | US | disclosed |
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | INNATE PHARMA (FR) | 2020-04-07 | — | — | US | disclosed |
| EP-3564259-A2 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2019-11-06 | — | — | EP | disclosed |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2019-10-08 | — | — | US | disclosed |
| WO-2019113227-A1 | PRODRUGS ACTIVATED BY REDUCTION IN THE CYTOSOL | YALE UNIVERSITY (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2019-06-06 | — | — | US | disclosed |
| CN-106631874-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-acetyl group -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-106631874-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-acetyl group -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-106631857-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-propiono -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-106631857-B | Arylamine nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-propiono -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-106631876-B | (2- the chloroethyl)-N '-myristoyl of nitrogen mustard derivatives N, N- bis- base-Isosorbide-5-Nitrae-phenylenediamine and preparation method thereof | 长安大学 | 2019-05-03 | — | — | CN | disclosed |
| CN-106631875-B | Nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-hexadecanoyl group -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-03 | — | — | CN | disclosed |
| CN-106631875-B | Nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-hexadecanoyl group -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-05-03 | — | — | CN | disclosed |
| CN-106631876-B | (2- the chloroethyl)-N '-myristoyl of nitrogen mustard derivatives N, N- bis- base-Isosorbide-5-Nitrae-phenylenediamine and preparation method thereof | 长安大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-2872894-B1 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2019-04-17 | — | — | EP | disclosed |
| US-10246510-B2 | KIR3DL2 binding agents | INNATE PHARMA (FR) | 2019-04-02 | — | — | US | disclosed |
| CN-106631856-B | Nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-benzoyl -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-03-19 | — | — | CN | disclosed |
| CN-106631856-B | Nitrogen mustard derivatives N, N- bis- (2- chloroethyl)-N '-benzoyl -1,4- phenylenediamine and preparation method thereof | 长安大学 | 2019-03-19 | — | — | CN | disclosed |
| EP-2897979-B1 | KIR3DL2 BINDING AGENTS | INNATE PHARMA (FR) | 2019-02-13 | — | — | EP | disclosed |
| EP-1909846-B1 | TRIAZOLE-CONTAINING RELEASABLE LINKERS, CONJUGATES COMPRISING THE SAME AND PROCESSES FOR THEIR PREPARATION | SYNTARGA BV (NL) | 2018-12-26 | — | — | EP | disclosed |
| US-10132799-B2 | Screening of conjugated antibodies | INNATE PHARMA (FR) | 2018-11-20 | — | — | US | disclosed |
| US-10071169-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2018-09-11 | — | — | US | disclosed |
| EP-2793949-B1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | INNATE PHARMA (FR) | 2018-07-31 | — | — | US | disclosed |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2018-07-12 | — | — | US | disclosed |
| US-20180071402-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2018-03-15 | — | — | US | disclosed |
| US-9764038-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2017-09-19 | — | — | US | disclosed |
| US-9717803-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2017-08-01 | — | — | US | disclosed |
| CN-106631874-A | Arylamine nitrogen mustard derivative N,N-bis(2-chloroethyl)-N'-acetyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631857-A | Aryl nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-propionyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631856-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-benzoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631857-A | Aryl nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-propionyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631856-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-benzoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631875-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-hexadecanoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631876-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-myristoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631875-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-hexadecanoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631876-A | Nitrogen mustard derivative N,N-di(2-chloroethyl)-N'-myristoyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106631874-A | Arylamine nitrogen mustard derivative N,N-bis(2-chloroethyl)-N'-acetyl-1,4-phenylenediamine and preparation method thereof | 长安大学 | 2017-05-10 | — | — | CN | disclosed |
| US-20160331842-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2016-11-17 | — | — | US | disclosed |
| US-9427478-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2016-08-30 | — | — | US | disclosed |
| US-20160114056-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2016-04-28 | — | — | US | disclosed |
| EP-3010547-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2016-04-27 | — | — | EP | disclosed |
| EP-3010548-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2016-04-27 | — | — | EP | disclosed |
| US-20160022833-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| EP-2968582-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | Innate Pharma (FR) | 2016-01-20 | — | — | EP | disclosed |
| US-20150346195-A1 | SCREENING OF CONJUGATED ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2015-12-03 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20150291692-A1 | KIR3DL2 BINDING AGENTS | INNATE PHARMA (FR) | 2015-10-15 | — | — | US | disclosed |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | ARARIS BIOTECH LTD (CH) | 2015-10-08 | — | — | US | disclosed |
| EP-2916872-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2015-09-16 | — | — | EP | disclosed |
| EP-2897979-A1 | KIR3DL2 BINDING AGENTS | Innate Pharma (FR) | 2015-07-29 | — | — | EP | disclosed |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| EP-2872894-A2 | SCREENING OF CONJUGATED ANTIBODIES | Innate Pharma (FR) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014202773-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202775-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2793949-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| EP-2793947-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014140300-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014072482-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014044681-A1 | KIR3DL2 BINDING AGENTS | INNATE PHARMA (FR) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014009426-A2 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2014-01-16 | — | — | WO | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092998-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092983-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| US-8309554-B2 | Hypoxia activated drugs of nitrogen mustard alkylators | THRESHOLD PHARMACEUTICALS (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309554-B2 | Hypoxia activated drugs of nitrogen mustard alkylators | THRESHOLD PHARMACEUTICALS (US) | 2012-11-13 | — | — | US | disclosed |
| US-8236985-B2 | Compounds and uses thereof | IMPERIAL INNOVATIONS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | THRESHOLD PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | THRESHOLD PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-7893023-B2 | Prodrugs activated by plasmin and their use in cancer chemotherapy | MEDAREX, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | disclosed |
| US-20100063144-A1 | COMPOUNDS AND USES THEREOF | IMPERIAL INNOVATIONS LTD (GB) | 2010-03-11 | — | — | US | disclosed |
| WO-2009140553-A2 | HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1037649-B1 | POLYMERIC PRODRUGS OF AMINO- AND HYDROXYL-CONTAINING BIOACTIVE AGENTS | ENZON INC (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7544477-B2 | Identifying oligopeptides using interaction-dependent enzyme activation system; high-throughput assay | KALOBIOS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090076176-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | MEDAREX, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| US-7402556-B2 | Prodrugs activated by plasmin and their use in cancer chemotherapy | MEDAREX, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-7335478-B2 | Reactivation-based molecular interaction sensors | KALOBIOS PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | disclosed |
| EP-1041995-B1 | TRIALKYL-LOCK-FACILITATED POLYMERIC PRODRUGS OF AMINO-CONTAINING BIOACTIVE AGENTS | ENZON INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050209320-A1 | Anti-cancer compounds and methods of use thereof | GTX, INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | disclosed |
| US-20040171562-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | E. R. SQUIBB & SONS, L.L.C. | 2004-09-02 | — | — | US | disclosed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | disclosed |
| EP-1064257-B1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1064253-B1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-6472435-B1 | ANTITUMOR ANTIPROLIFERATION AGENT FORMED BY AMIDATION OF CARBOXY ACID WITH AROMATIC AMINE COMPOUND | ASTRAZENECA AB (SE) | 2002-10-29 | — | — | US | disclosed |
| EP-0711768-B1 | BENZIMIDAZOLE DERIVATIVE | MITSUI CHEMICALS INC (JP) | 2002-02-13 | — | — | EP | disclosed |
| US-6346633-B1 | TERT-AMINOPHENYLESTER OF ACID | ASTRAZENECA AB (SE) | 2002-02-12 | — | — | US | disclosed |
| US-6303569-B1 | POLYMERIC-BASED DOUBLE PRODRUGS HAVING REVERSIBLE LINKAGES INVOLVING AMINO OR HYDROXYL MOIETIES OF CHEMICAL COMPOUNDS AND BIOLOGICALLY ACTIVE MATERIALS SUCH AS ENZYMES, PROTEINS | ENZON, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6180095-B1 | FOR DRUG DELIVERY | ENZON, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-1064253-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| EP-1064257-A1 | ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | disclosed |
| US-6011042-A | POLYMERIC PRODRUGS ARE PREFERABLY ESTERS OF HYDROXYL-CONTAINING AROMATIC COMPOUNDS AND ARE FORMED BY REACTING A DESIRED AROMATIC, HYDROXYL-CONTAINING COMPOUND WITH A SUBSTANTIALLY NON-ANTIGENIC POLYMER | ENZON, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5965119-A | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents | ENZON, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999048857-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999048860-A1 | ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 1999-09-30 | — | — | WO | disclosed |
| US-5872129-A | REACTING AROMATIC ALPHA-METHYL HALIDES WITH N-ALKYL OR N-ARYLDIETHANOLAMINES TO GIVE QUATERNARY DIOLS AND CONVERTING DIOLS TO HALOGEN OR SULFONATE DERIVATIVES BY TREATING WITH SULFONYL CHLORIDE; ANTITUMOR BLOOD FLOW AGENT | AUCKLAND UNISERVICES LIMITED (NZ) | 1999-02-16 | — | — | US | disclosed |
| EP-0891191-A1 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5852011-A | Benzimidazole derivatives | MITSUI CHEMICALS, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-5821258-A | ANTICARCINOGENIC AGENTS; ANTIVIRAL AGENTS; ANTIMICROBIAL AGENTS | MITSUI CHEMICALS, INC. (JP) | 1998-10-13 | — | — | US | disclosed |
| US-5773435-A | ANTITUMOR AGENTS USING CEPHALOSPORINS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5691371-A | ANTITUMOR AND -CARCINOGENIC AGENTS; PRODRUGS BIOREDUCED TO RELEASE A CYTOTOXIN, A MECHLORETHAMINE DERIVATIVE; WATER SOLUBLE | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-11-25 | — | — | US | disclosed |
| WO-1997036616-A2 | ANTI-TUMOUR AGENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1997-10-09 | — | — | WO | disclosed |
| EP-0745390-A2 | Polymeric prodrugs for beta-lactamase and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0742015-A1 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0719765-A2 | Phenylbenzimidazole derivatives | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-03 | — | — | EP | disclosed |
| EP-0700376-A4 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LTD (NZ) | 1996-05-22 | — | — | EP | disclosed |
| EP-0711768-A1 | BENZIMIDAZOLE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0700376-A1 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994027954-A1 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 1994-12-08 | — | — | WO | disclosed |
| EP-0484870-A2 | Prodrugs for beta-lactamase and uses thereof | Bristol-Myers Squibb Company (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0192242-B1 | SUBSTITUTED AMINOPHENYLUREA DERIVATIVES | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4803223-A | ANTITUMOR AGENTS | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1989-02-07 | — | — | US | disclosed |
| US-4017471-A | ANTITUMOR AGENT | G. D. SEARLE & CO. (EN) | 1977-04-12 | — | — | US | disclosed |
| US-4017471-A | ANTITUMOR AGENT | G. D. SEARLE & CO. (EN) | 1977-04-12 | — | — | US | disclosed |
| US-4017471-A | ANTITUMOR AGENT | G. D. SEARLE & CO. (EN) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (35 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | HIF1AN, HIF1A, HYOU1 | CYP3A4 567/4885ALDH1A1 325/4885TDP1 1240/4885 |
| US-20200384002-A1 | Prodrugs Activated by Reduction in the Cytosol | TK1, MTHFD1, GOT1 | CYP3A4 302/4885ALDH1A1 1315/4885TDP1 571/4885 |
| US-10675359-B2 | Enzymatic conjugation of antibodies | DNPEP, MPO, FCGR3B | CYP3A4 306/4885ALDH1A1 161/4885TDP1 1163/4885 |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | CYP3A4 306/4885ALDH1A1 161/4885TDP1 1163/4885 |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CYP3A4 737/4885ALDH1A1 484/4885TDP1 949/4885 |
| US-10246510-B2 | KIR3DL2 binding agents | KLRK1, KCNA3, KCNK3 | CYP3A4 2294/4885ALDH1A1 1403/4885TDP1 4398/4885 |
| US-20180071402-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CYP3A4 636/4885ALDH1A1 468/4885TDP1 914/4885 |
| US-10611824-B2 | Solid phase TGase-mediated conjugation of antibodies | TGM3, TGM2, TGM6 | CYP3A4 204/4885ALDH1A1 1703/4885TDP1 879/4885 |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | CYP3A4 1084/4885ALDH1A1 1144/4885TDP1 684/4885 |
| US-20240156987-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | STING1, MITF, RARA | CYP3A4 4878/4885ALDH1A1 1410/4885TDP1 448/4885 |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | CYP3A4 210/4885ALDH1A1 1189/4885TDP1 2056/4885 |
| US-20230015146-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | STING1, MITF, RARA | CYP3A4 4878/4885ALDH1A1 1410/4885TDP1 448/4885 |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | CYP3A4 561/4885ALDH1A1 415/4885TDP1 696/4885 |
| US-11826399-B2 | Chlorotoxin agents and uses thereof | NRP1, LCP1, CLSPN | CYP3A4 3246/4885ALDH1A1 612/4885TDP1 676/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | CYP3A4 680/4885ALDH1A1 613/4885TDP1 925/4885 |
| US-10132799-B2 | Screening of conjugated antibodies | FCGR2A, TGM2, TGM6 | CYP3A4 2934/4885ALDH1A1 2044/4885TDP1 3189/4885 |
| US-20250297004-A1 | NECTIN-4 BINDING AGENTS | NECTIN4, VCAM1, EPCAM | CYP3A4 2890/4885ALDH1A1 1865/4885TDP1 4431/4885 |
| US-20090076176-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | PLG, PLAT, DNPEP | CYP3A4 908/4885ALDH1A1 2535/4885TDP1 1288/4885 |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | TGM2, TGM3, TGM6 | CYP3A4 2693/4885ALDH1A1 3578/4885TDP1 1188/4885 |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | CYP3A4 306/4885ALDH1A1 161/4885TDP1 1163/4885 |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | CYP3A4 2693/4885ALDH1A1 3578/4885TDP1 1188/4885 |
| US-20150346195-A1 | SCREENING OF CONJUGATED ANTIBODIES | FCGR2A, TGM2, TGM6 | CYP3A4 2934/4885ALDH1A1 2044/4885TDP1 3189/4885 |
| US-20040171562-A1 | Prodrugs activated by plasmin and their use in cancer chemotherapy | PLG, PLAT, DNPEP | CYP3A4 908/4885ALDH1A1 2535/4885TDP1 1288/4885 |
| US-20160114056-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CYP3A4 665/4885ALDH1A1 161/4885TDP1 559/4885 |
| US-10071169-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | CYP3A4 665/4885ALDH1A1 161/4885TDP1 559/4885 |
| US-20160022833-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | TGM2, TGM3, TGM6 | CYP3A4 202/4885ALDH1A1 1768/4885TDP1 800/4885 |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | CYP3A4 2693/4885ALDH1A1 3578/4885TDP1 1188/4885 |
| US-20150291692-A1 | KIR3DL2 BINDING AGENTS | MICA, NECTIN4, PDCD6 | CYP3A4 1267/4885ALDH1A1 2721/4885TDP1 4351/4885 |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | CYP3A4 3812/4885ALDH1A1 1712/4885TDP1 43/4885 |
| US-20160331842-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CYP3A4 561/4885ALDH1A1 415/4885TDP1 696/4885 |
| US-11904023-B2 | Nucleic acid products and methods of administration thereof | STING1, MITF, RARA | CYP3A4 4878/4885ALDH1A1 1410/4885TDP1 448/4885 |
| US-20240325557-A1 | TREATMENT OF CANCER | NECTIN4, CD44, EPCAM | CYP3A4 4347/4885ALDH1A1 1534/4885TDP1 3839/4885 |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CYP3A4 561/4885ALDH1A1 415/4885TDP1 696/4885 |
| US-20100063144-A1 | COMPOUNDS AND USES THEREOF | HDAC1, HDAC11, HDAC2 | CYP3A4 251/4885ALDH1A1 150/4885TDP1 751/4885 |
| US-20050209320-A1 | Anti-cancer compounds and methods of use thereof | AR, BRDT, BAD | CYP3A4 3312/4885ALDH1A1 1269/4885TDP1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.